is mounjaro a glp 1 agonist Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), major breakthrough for the treatment of obesity Mounjaro vs Ozempic: Understanding the

Living with hemophilia means balancing many aspects of daily health, from managing bleeding risks to being mindful of possible medication interactions

Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users

Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive

This update elevates obesity within the global noncommunicable disease agenda and sets a clear mandate for action

Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)

GIP Receptor Antagonism (Blocking): Unlike many dual-agonists that activate GIP, MariTide blocks it